Gleevec

Adjuvant Gleevec, Star of ASCO: What We Learned

Results of the Scandinavian Sarcoma Group (SSG 18) adjuvant imatinib (Gleevec/Glivec) trial in high risk GIST were presented on June 5, during the Plenary Session of the 2011 American Society of Clinical Oncology conference (ASCO). The Plenary or “all members’ session” highlights “abstracts deemed to have the highest merit and greatest impact on oncology research and practice”.

By |2018-10-30T14:04:38-04:00August 1st, 2011|Gleevec, News|

Tasigna shows greater efficacy over Gleevec for CML: Will GIST be next?

For the past eight years, Gleevec has been the first-line treatment for adult patients with c-Kit (CD117)-positive, unresectable and/or metastatic malignant GISTs. But for some patients, Gleevec is not the answer to their prayers. A small percentage, five to 15 percent, do not benefit from Gleevec from the outset. Others develop a resistance to the drug or cannot tolerate the side effects.

By |2019-12-26T15:37:41-05:00February 1st, 2010|Gleevec, News|

Gleevec Receives FDA Priority Review

Gleevec receives FDA priority review as first therapy to reduce recurrence of GI stromal tumors after surgery East Hanover, August 27, 2008 — Novartis announced today that Gleevec® (imatinib mesylate) tablets has been granted priority [...]

By |2019-12-30T10:57:35-05:00September 2nd, 2008|Gleevec|

Suboptimal response in CML linked to Gleevec uptake in cells

Australian researchers have confirmed the protein involved in Gleevec’s transport into chronic myelogenousleukemia (CML) cells and have shown that it is the activity of this protein which is a key determinant of response in CML patients.

By |2019-09-16T12:10:54-04:00February 4th, 2008|Gleevec|

Immunotherapy Trial Strives to Improve Gleevec Response

2011 Update - Clinical trial results published open access in Cancer Immunology Immunotherapy. ". . . Interim analysis of eight patients demonstrated significant induction of IFN-γ-producing-CD8+, -CD4+, -NK cell, and IFN-γ-producing-tumor-infiltrating-lymphocytes, signifying significant Th1 response [...]

By |2018-07-09T10:38:36-04:00May 1st, 2007|Clinical Trials, Gleevec, News|

Gleevec: Revolutionizing GIST Cancer Treatment

In this month’s March 2007 newsletter, Estelle LeCointe, the director of Association Française des Patients du GIST: Ensemble contre le GIST, has shared the story of the work of Professor Laurence Zitvogel. Professor Zitvogel and her colleagues are engaged in a project combining Gleevec and immunotherapy. It has been very interesting to watch this work evolve over the last few years. This research has culminated in the discovery of a new type of immune cell (in mice) and is poised to enter clinical trials in 2007.

By |2018-07-06T15:09:43-04:00March 1st, 2007|Gleevec, News|
Go to Top